Navigation Links
DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round

EVRY, France, January 29 /PRNewswire/ -- DNA Therapeutics, an emerging biopharmaceutical company specialized in the development of innovat0ive medicines in oncology, announces the successful closing of its Series A equity investment round. The investor syndicate led by SGAM SEFTI with two of the previous seed investors, Blue Medical Investments and G1J-Ile de France, is committed to invest 2.2 million EUR based on certain milestones to be met. Since June 2008, DNA Therapeutics has raised 3 million EUR (US$4 million) through the current Series A and the previous seed financing round led by Inserm-Transfert Initiative.

The funds will enable DNA Therapeutics to advance the vectorization and the additional proofs of concept, and to achieve regulatory preclinical studies of its lead product, named Dbait. DNA Therapeutics is developing a new class of drugs fighting tumor resistance to conventional therapies. In current cancer treatment, the effectiveness of radiotherapy and chemotherapy are often limited by the action of DNA repair processes on the damages caused by these therapies. The innovative aspect of siDNA (signal interfering DNA) technology developed in DNA Therapeutics is to use a short fragment of DNA, a mimetic of DNA damage, to interfere with the sensing and signaling of DNA damages in the nucleus, and ultimately, inhibit their repair during the treatment period. Thus siDNA increases the effectiveness of radiotherapy and chemotherapy without adding any cytotoxic effect. The company possesses a portfolio of exclusive worldwide licenses resulting from the pioneering work of its founding scientists at the Institut Curie, the CNRS, the INSERM (French NIH) and the French National Museum of Natural History.

Prof. Jian-Sheng Sun, co-founder, Chairman and CEO commented: "We are delighted to have received this significant investment from SGAM SEFTI that is strongly committed to support Life Science innovation at early stage in France and in Europe, and that shares our business vision and values the potential of our drug development based on our unique proprietary siDNA technology. This financing will allow DNA Therapeutics to move ahead with an aggressive timeline for the preclinical development of Dbait which will enter into phase I/II clinical trial by the end of 2010."

"Since January 2006, we have been carrying out fundamental work consisting of creating and shaping our company portfolio to meet SEFTI's objectives. This effort has resulted in an original portfolio companies, mainly in France and Switzerland, close to clinical stage, and attractive to big biotech, pharmaceutical and medical device companies. Adding DNA Therapeutics, which develops a breakthrough treatment in oncology, to SEFTI's portfolio companies, is in line with our innovative investment strategy. Today, SGAM SEFTI has already invested, or is ready to invest in near term, more than half of the fund's commitments," said Beatrice Denys, manager of the fund. "The life of the fund is entering a second phase in which one of our priorities will be to endeavor to demonstrate the validity of our investment choices, notably through the emphasis placed on organizing output," added Eric Viaud, exclusive advisor of SEFTI.

About DNA Therapeutics

DNA Therapeutics SA ( headquartered in the Genopole biocluster (Evry, France) was founded in June 2006. Its original siDNA technology consists in interfering with DNA repair pathways that cancer cells use to resist radiotherapy and chemotherapy. Its lead product, Dbait, will be first administered locally in combination with radiotherapy in selected indications where radiotherapy is used as standard of care but fails due to radio-resistance. After its first clinical validation, the systemic administration of Dbait will expand its scope to all indications currently treated by radiotherapy and chemotherapy. The ability of siDNA to improve therapeutic efficacy without additional cytotoxicity has potential to extend the market for radiotherapy and chemotherapy. It is anticipated that DNA Therapeutics will have a pipeline with products at different stages of development within the next 5 years, throughout balanced proprietary and partnered programs, thus achieving rapidly significant value creation and providing the exit opportunity for its initial investors.


SGAM SEFTI (Specialized European fund for Therapeutic Innovation) is a venture fund dedicated to investments in unlisted French and European companies operating principally in the pharmaceutical field and in medico-surgical applications. The fund acquires interests in the firms which it accompanied through the set-up stage in order to develop and increase the value of innovative therapeutic projects coming mainly from academic research in France, Switzerland and Italy. SGAM SEFTI investment is focused in target companies at an initial stage of development and which have further development opportunities with the potential to provide a capital gain in the medium term through licensing and sale.


    DNA Therapeutics
    Prof. Jian-Sheng Sun, Ph.D.
    Chairman and CEO
    Phone: +33-624-753-239

    Dr. Beatrice Denys, M.D., MBA
    Manager of the fund
    Phone: +33-156-378-712

SOURCE DNA Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
2. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
3. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
4. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
7. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
8. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
9. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
10. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
11. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
Post Your Comments:
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Italian therapeutic drug monitoring market, including ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
(Date:11/25/2015)... MINNEAPOLIS , Nov. 25, 2015  ARKRAY ... care products, continues to provide evidence demonstrating the accuracy ... the World Congress on Insulin Resistance, Diabetes and Cardiovascular ... showed that both the Company,s GLUCOCARD ® 01 ... met high accuracy requirements. The ability to accurately measure ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... ... direct sauna parts and accessories. , Sauna accessories help improve the bather experience ... and personality. From basic styles for the purist looking for simplicity in design ...
(Date:11/25/2015)... ... 2015 , ... For the first time, Vitalalert is donating half of its ... The partnership between the two groups began in 2014 with Vitalalert pledging a portion ... International was founded in 1954 and is an international Christian-based health organization whose mission ...
(Date:11/25/2015)... , ... November 25, 2015 , ... On November 25, ... center for the Narconon network, announced the release of a new cutting edge recovery ... Narconon organization has been working with drug- and alcohol-addicted individuals with the purpose to ...
(Date:11/25/2015)... ... 2015 , ... Smiles by Stevens is pleased to announce the ... While many patients are aware of the benefits of Botox® in the treatment of ... suffering with discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... In an ... Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of ... and surgical intensive care units (totaling 30 beds) from May 2014 through October 2015 ...
Breaking Medicine News(10 mins):